Mining gene expression data by interpreting principal components by Roden, Joseph C et al.
BioMed  Central
Page 1 of 22
(page number not for citation purposes)
BMC Bioinformatics
Open Access Software
Mining gene expression data by interpreting principal components
Joseph C Roden*1, Brandon W King2, Diane Trout2, Ali Mortazavi2, 
Barbara J Wold2 and Christopher E Hart2
Address: 1Jet Propulsion Laboratory, California Institute of Technology, Pasadena, USA and 2Division of Biology, California Institute of 
Technology, Pasadena, USA
Email: Joseph C Roden* - joe.roden@jpl.nasa.gov; Brandon W King - kingb@caltech.edu; Diane Trout - diane@caltech.edu; 
Ali Mortazavi - alim@caltech.edu; Barbara J Wold - woldb@caltech.edu; Christopher E Hart - hart@caltech.edu
* Corresponding author    
Abstract
Background: There are many methods for analyzing microarray data that group together genes
having similar patterns of expression over all conditions tested. However, in many instances the
biologically important goal is to identify relatively small sets of genes that share coherent
expression across only some conditions, rather than all or most conditions as required in
traditional clustering; e.g. genes that are highly up-regulated and/or down-regulated similarly across
only a subset of conditions. Equally important is the need to learn which conditions are the decisive
ones in forming such gene sets of interest, and how they relate to diverse conditional covariates,
such as disease diagnosis or prognosis.
Results: We present a method for automatically identifying such candidate sets of biologically
relevant genes using a combination of principal components analysis and information theoretic
metrics. To enable easy use of our methods, we have developed a data analysis package that
facilitates visualization and subsequent data mining of the independent sources of significant
variation present in gene microarray expression datasets (or in any other similarly structured high-
dimensional dataset). We applied these tools to two public datasets, and highlight sets of genes
most affected by specific subsets of conditions (e.g. tissues, treatments, samples, etc.). Statistically
significant associations for highlighted gene sets were shown via global analysis for Gene Ontology
term enrichment. Together with covariate associations, the tool provides a basis for building
testable hypotheses about the biological or experimental causes of observed variation.
Conclusion:  We provide an unsupervised data mining technique for diverse microarray
expression datasets that is distinct from major methods now in routine use. In test uses, this
method, based on publicly available gene annotations, appears to identify numerous sets of
biologically relevant genes. It has proven especially valuable in instances where there are many
diverse conditions (10's to hundreds of different tissues or cell types), a situation in which many
clustering and ordering algorithms become problematic. This approach also shows promise in
other topic domains such as multi-spectral imaging datasets.
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Background
Bioinformatics has placed much emphasis on using vari-
ous unsupervised clustering techniques as a means to
understand the information present in gene microarray
expression datasets. Clustering techniques produce a rich
taxonomy of results by defining groups of genes that act
more or less similarly across a number of experimental
conditions. The diverse approaches to clustering genes by
expression levels include k-means [1], self-organizing
maps [2], hierarchical algorithms [3,4] and probabilistic
models [5]. Some approaches permit clustering of the
conditions as well [6-8]. Based on co-expression, genes
that comprise individual expression clusters are often pos-
tulated to be co-regulated, and to the extent that this
hypothesis is correct in any specific biological situation,
the gene cluster definitions can offer key insights into
gene regulatory network (GRN) structure and function.
Another common data mining task is to try to identify
small sets of genes that can serve as effective predictors of
disease diagnosis or prognosis. While clustering at its best
is good at finding sets of genes that are similarly expressed
across all conditions within a dataset, many issues (e.g.
selection of K, stochastic effects, and "noise" from large
numbers of genes that change little over most of the con-
ditions) can prevent clustering from successfully high-
lighting small groups of interestingly co-expressed genes
[9,10]. This often encountered problem is addressed in
part by hierarchical phylogenetic ordering algorithms
such as average linkage in Mike Eisen's cluster program
[3], but the information biologists seek regarding shared
sub-patterns of co-expression can be obscured by both
algorithmic and visualization constraints. The algorithmic
limitations in hierarchical clustering confound and
"cover" the presence and organization of smaller and
more specific gene groups that are similar across only a
subset of conditions within the larger dataset. In any case,
biologists generally subjectively define a cluster of genes
from such phylogenetic trees based largely on human pat-
tern recognition. Finally, nothing inherent in the cluster-
ing approach helps to direct a biologist to which cluster is
interesting or relevant. Instead, biologists generally take
the path of focussing on a group of genes exhibiting a pat-
tern of expression that supports a specific hypothesis, or
search for a known gene or genes of interest within a clus-
ter to form an explanation for others in the cluster.
Support vector machines have been shown to be useful for
identifying small sets of related and predictive genes [11-
14], but represent a supervised learning approach which
requires one to first define a set of known positive exam-
ples, a set of known negative examples, and a specific cov-
ariate to predict. We wanted an unsupervised algorithm
that would help us to find relationships and structure in
the data that is more specific than what clustering algo-
rithms usually deliver, yet is hypothesis independent. We
found it efficient and useful to use as an independent
starting tool a very direct approach based on principal
components analysis (PCA, see Methods section). A virtue
is that this approach is computationally efficient for very
large datasets, especially compared with most clustering
algorithms, but is also applicable to much smaller ones. It
allows one to directly explore each of the independent
and diverse sources of variation present within a gene
expression dataset and to subsequently identify the spe-
cific genes that vary the most, together with the conditions
in which they vary.
Unlike conventional clustering and ordering algorithms,
this PCA based approach permits a gene to be highlighted
and grouped as influential in multiple condition sets,
whereas in cluster membership a gene is typically assigned
to one unique cluster. The "single cluster assignment"
quality of traditional clustering and ordering algorithms is
problematical because it tends to hide commonality of
expression that is restricted to a small, interesting, and
often entirely unpredicted subgroups of tissues, cell types,
treatments or other condition types. This situation, per-
haps because of inherent properties of gene network struc-
ture, will arise increasingly as the number and diversity of
conditions represented in expression datasets increases.
The clustering method of Barkai et al. [15,16] addresses
this issue of multiple membership in a different way, by
using randomly-selected gene sets to iteratively search for
and refine self-consistent groups. Their approach, which is
related to PCA through singular value decomposition
(SVD), also permits genes to be assigned to multiple
"expression modules." In contrast to the method pre-
sented here, there is no provision for correlating modules
with covariate data.
The use of principal components analysis presented here
differs from other recent applications in gene expression
analysis. PCA is most commonly used in as a means of
dimensionality reduction prior to clustering [7,17] or
prior to classification [18,19]. It is also used to visualize or
confirm clustering results [19-21]. In contrast, our use of
PCA aims to find, then examine, and where possible, gen-
erate hypotheses to explain individual principal compo-
nents. In this manner, we build on the observations by
Hilsenbeck [22] Raychaudhuri et. al. [23] who used PCA
to gain insight into the underlying factors present in the
Chu et. al. yeast sporulation experiments [24]. Wall et. al.
[25] introduced a novel use of singular value decomposi-
tion (SVD) for gene expression analysis that identifies
non-exclusive gene groups, and Selaru et. al. [26] illus-
trated the potential of PCA to detect molecular pheno-
typic bases that correspond to relevant clinical or
biological features of human tumors. Their approachBMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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identifies a subset of principal components that correlate
well with known covariates. Here we introduce methods
that extend beyond producing gene groups and observing
a few principal components. Our methods provide a path
for systematically analyzing each principal component by
identifying the genes most influential in defining a partic-
ular principal component and the conditions in which
those influential genes vary significantly. Finally, we
describe methods which aim to explain each principal
component's observed variance in terms of the condition
variables deemed most likely to be driving the variance.
We also introduce a software package that implements
these methods. These methods and our software package
provide automated and objective way of doing what a
biologist naturally tries to do through inspection and pat-
tern recognition.
Implementation
We have developed a Python package to implement the
PCA interpretation capability described in detail in the
Methodology section. This PCA analysis package has been
added to CompClust developed previously [9,27]. The
combined packages allow one to cluster, classify and visu-
alize numeric datasets that have discrete or numeric anno-
tations (referred to as labelings, or labelled datasets), and
to compare labelings with confusion matrices and metrics
such as normalized mutual information (NMI) [28]. This
PCA analysis tool (including the complete results for the
dataset analysis described in the Results section) has also
been made accessible through the CompClustWeb web-
based interface [29]. Our software makes use of data
manipulation and graphical plotting using the matplotlib
package [30], and the statistics are generated using the rPy
package [31] and Gary Strangman's Python stats package
[32].
The web-based front-end permits users to get a complete
report on the interpretation of each principal component,
including interactive PCA projection plots with the princi-
pal component's extreme genes (PCEGs) highlighted;
ranked lists of the PCEGs with detailed annotations; inter-
active significance-ordered gene set trajectory plots that
permit users to drill down to the individual gene level;
similarly ordered condition reports ordered by expression
difference and grouped by significance, including covari-
ate info (with significantly correlated covariates high-
lighted); and finally a report of any suggestive covariates
that are well correlated with the significant column group-
ing, including the confusion matrices and/or plots of sta-
tistics scores to back up the conclusions. All principal
component analysis and results generation is imple-
mented in a Python package so that analyses of large data-
sets can be executed in a batch mode rather than through
the graphical interface. Further, the software that imple-
ments the CompClustWeb interface is provided within
the CompClust package, so a software developer can cre-
ate his or her own CompClustWeb server to review results
of their PCA interpretation.
Results
Application to microarray expression data, Case 1: GNF 
human data
We obtained gene expression data from the Genomics
Institute of the Novartis Research Foundation ("GNF")
Gene Expression Database via their SymAtlas web site
[33,34]. The dataset is a challenge for most clustering
algorithms because it contains 158 tissue samples hybrid-
ized to two Affymetrix microarray chips: U133A and
GNF1H. The dataset combines the measurements of these
chips to provide a total of 33,689 unique probe identities
across the 158 tissue samples. Expression data are signal
intensities estimated by Affymetrix Microarray Suite v5.
For our analysis we used the log base 2 of the expression
signal, and included data for all tissues and probes (not-
ing that absent and present calls were not provided with
the signal intensities). We applied our principal compo-
nents analysis tool to generate interpretations for each of
this dataset's 158 principal components.
As detailed in the Methodology section, for each principal
component we identified a set of gene probes occupying
the high and low extremes of that principal component's
axis (we refer to these as principal component extreme
genes, or PCEGs). One can adjust parameters to recover
smaller and larger numbers of PCEGs per component by
specifying either a likelihood threshold or an explicit
number of PCEGs. The PCEGs are those probes having the
most highly weighted values for that principal compo-
nent, selected because they stand out from the others, they
influence the principal component's direction, and thus
they warrant further investigation. We selected probes
with likelihoods less than extremeThresh = 0.00001, which
yielded on average 20 low and 20 high extreme genes per
principal component, though the sets sizes do vary con-
siderably (µ = 18.9, σ = 17.2). Next we identified the tis-
sues in which the high PCEGs showed significantly
different expression than the low PCEGs. Visualizations
produced include scatter plots of the extreme genes in
PCA sub-spaces (PC N-1vs. PC N), and extreme gene tra-
jectories in original tissue order as well as with tissues
ordered by decreasing difference of mean of high PCEGs
and mean of low PCEGs. The latter trajectory plot empha-
sizes how the extreme genes for a principal component
show a pattern of expression that imposes a partitioning
of tissues. It is left to human interpretation to examine the
extreme genes and the tissue partitioning exposed by each
principal component, and thus to build hypotheses that
attach meaning to the sources of variation. The percentage
variance explained by the top 50 principal components is
provided in Table 1. Example results for two illustrativeBMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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principal components, PC7 and PC21, are shown in Fig-
ures 1 through 4 and in Tables 2 through 5, and are dis-
cussed below. The complete analysis results generated for
PC7 are provided as an example in the supplemental files:
[see Additional file 1], [see Additional file 2], [see Addi-
tional file 3], [see Additional file 4], [see Additional file 5],
[see Additional file 6]. Our supplemental materials web
site [35] contains the complete collection of PCA interpre-
tation results generated for these dataset for all principal
components, as well as results of a comparable analysis
done at extremeThresh = 0.001 which yielded larger PCEG
sets.
We addressed the question of biological and statistical sig-
nificance of PCs and the sets of extreme genes identified.
Each set of high and low extreme genes from each princi-
pal component was tested for Gene Ontology (GO) statis-
tical enrichment when compared to the human GO
annotations from NCBI's loc2go dataset using the hyper-
geometric to calculate the p-value of each GO term. Terms
that were enriched for a particular PC at 1% significance
threshold and that were still significant following a Bon-
ferroni correction for multiple hypothesis testing as
described in [36] are reported as enriched (see Table 6).
26 of the top 42 PCEG lists, derived using a stringent cut-
off of 0.00001, produced significant GO enrichments; no
PCEG sets beyond PC42 showed significant enrichment.
As discussed below, many of the significant results
showed obvious biological coherence and relationships
to the specific samples associated with the PC of origin.
This argues that PCs containing less than 1% of the total
variation in this dataset are still relevant and point to
coherent and important gene sets and their related sam-
ples.
Relationships between extreme gene sets and the corre-
sponding sets of driving samples could be discerned for
many PCs. The Methodology section presents a way to
additionally correlate each principal component's sample
partitioning with any available sample covariates.
Although some human sample covariate information is
provided in our test case, the GNF human expression
dataset is not amenable to this additional layer of analysis
because multiple subject's RNA samples were pooled
prior to amplification and array hybridization. However,
a second publicly available dataset with rich covariate
information is presented below.
Application to microarray expression data, case 2: human 
diabetes
We acquired a Human diabetes expression dataset [37]
from the Broad Institute Cancer Program dataset reposi-
tory [38] along with the corresponding phenotype covari-
ate data, and applied the filtering step as they described to
produce a set containing 10,983 probes across 43 sam-
Table 1: Variance Explained By Principal Components. Table 1 
lists the percentage of variance in the GNF human tissue 
microarray data explained by each principal component. The 
first 10 components explain 80.36% of the total variance. 
Principal components 11 through 158 each explain less than 0.5% 
of the total variance, but combined explain almost 20%.
Principal Component Percentage of Variance
1 67.62
24 . 6 6
32 . 0 4
41 . 4 1
51 . 0 7
60 . 9 0
70 . 8 1
80 . 6 9
90 . 6 3
10 0.54
11 0.46
12 0.42
13 0.37
14 0.35
15 0.32
16 0.31
17 0.30
18 0.29
19 0.26
20 0.26
21 0.25
22 0.24
23 0.23
24 0.22
25 0.22
26 0.22
27 0.21
28 0.20
29 0.20
30 0.19
31 0.19
32 0.19
33 0.18
34 0.18
35 0.18
36 0.18
37 0.17
38 0.16
39 0.16
40 0.16
41 0.16
42 0.16
43 0.16
44 0.15
45 0.15
46 0.15
47 0.15
48 0.15
49 0.14
50 0.14BMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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Table 2: PC7 High Extreme Genes. Detailed info for (n = 88) extreme genes in PC7 set H7, ordered most extreme first, including 
common name, description, and associated Gene Ontology terms (provided with the GNF dataset). These extreme genes are shown 
as red points in Figure 1.
PC-7 Value Name Description Function
18.63 COL1A2 collagen, type I, alpha 2 (GO:0006817) phosphate transport; (GO:0001501) skeletal development; (GO:0008147) structural 
constituent of bone;
17.89 LUM lumican (GO:0005518) collagen binding; (GO:0030199) collagen fibril organization; (GO:0005207) 
extracellular matrix glycoprotein; (GO:0005201) extracellular matrix structural constituent; 
(GO:0005203) proteoglycan; (GO:0007601) visual perception;
15.48 TPM2 tropomyosin 2 (beta) (GO:0003779) actin binding; (GO:0007517) muscle development; (GO:0008307) structural 
constituent of muscle;
15.30 IGFBP7 insulin-like growth factor binding 
protein 7
(GO:0005520) insulin-like growth factor binding; (GO:0008285) negative regulation of cell 
proliferation; (GO:0001558) regulation of cell growth;
14.54 CAV1 caveolin 1, caveolae protein, 22 
kDa
(GO:0005198) structural molecule activity; (GO:0008181) tumor suppressor;
14.08 COL3A1 collagen, type III, alpha 1 (Ehlers-
Danlos syndrome type IV, 
autosomal dominant)
(GO:0008015) circulation; (GO:0005202) collagen; (GO:0005201) extracellular matrix structural 
constituent; (GO:0007397) histogenesis and organogenesis; (GO:0009887) organogenesis; 
(GO:0006817) phosphate transport;
13.84 KCTD12 potassium channel 
tetramerisation domain 
containing 12
(GO:0006813) potassium ion transport; (GO:0005515) protein binding; (GO:0005249) voltage-
gated potassium channel activity;
13.83 COL1A1 collagen, type I, alpha 1 (GO:0005202) collagen; (GO:0005201) extracellular matrix structural constituent; (GO:0007605) 
perception of sound; (GO:0006817) phosphate transport; (GO:0001501) skeletal development; 
(GO:0008147) structural constituent of bone;
13.71 MGP matrix Gla protein (GO:0005509) calcium ion binding; (GO:0005201) extracellular matrix structural constituent; 
(GO:0007048) oncogenesis; (GO:0007605) perception of sound; (GO:0008147) structural 
constituent of bone;
13.57 COL3A1 collagen, type III, alpha 1 (Ehlers-
Danlos syndrome type IV, 
autosomal dominant)
(GO:0008015) circulation; (GO:0005202) collagen; (GO:0005201) extracellular matrix structural 
constituent; (GO:0007397) histogenesis and organogenesis; (GO:0009887) organogenesis; 
(GO:0006817) phosphate transport;
13.25 CALD1 caldesmon 1 (GO:0003779) actin binding; (GO:0005516) calmodulin binding; (GO:0006936) muscle contraction; 
(GO:0007517) muscle development; (GO:0017022) myosin binding; (GO:0005523) tropomyosin 
binding
13.19 MYL9 myosin, light polypeptide 9, 
regulatory
(GO:0005509) calcium ion binding; (GO:0008307) structural constituent of muscle
13.12 FN1 fibronectin 1 (GO:0006953) acute-phase response; (GO:0007155) cell adhesion; (GO:0016477) cell migration; 
(GO:0005518) collagen binding; (GO:0005201) extracellular matrix structural constituent; 
(GO:0008201) heparin binding; (GO:0009611) response to wounding
12.71 PLK2 polo-like kinase 2 (Drosophila) (GO:0005524) ATP binding; (GO:0043123) positive regulation of I-kappaB kinase/NF-kappaB 
cascade; (GO:0006468) protein amino acid phosphorylation; (GO:0004674) protein serine/
threonine kinase activity; (GO:0004871) signal transducer activity; (GO:0016740) transferase 
activity
12.59 CALD1 caldesmon 1 (GO:0003779) actin binding; (GO:0005516) calmodulin binding; (GO:0006936) muscle contraction; 
(GO:0007517) muscle development; (GO:0017022) myosin binding; (GO:0005523) tropomyosin 
binding
12.54 CTGF connective tissue growth factor (GO:0006259) DNA metabolism; (GO:0007155) cell adhesion; (GO:0005194) cell adhesion 
molecule activity; (GO:0008151) cell growth and/or maintenance; (GO:0006928) cell motility; 
(GO:0008201) heparin binding; (GO:0005520) insulin-like growth factor binding; (GO:0005515) 
protein binding; (GO:0001558) regulation of cell growth; (GO:0009611) response to wounding
12.39 D2S448 Melanoma associated gene (GO:0006955) immune response; (GO:0005152) interleukin-1 receptor antagonist activity; 
(GO:0004601) peroxidase activity
12.28 MFAP5 microfibrillar associated protein 
5
(GO:0005201) extracellular matrix structural constituent
12.24 SEMA3C sema domain, immunoglobulin 
domain (Ig), short basic domain, 
secreted, (semaphorin) 3C
(GO:0008151) cell growth and/or maintenance; (GO:0007275) development; (GO:0009315) drug 
resistance; (GO:0006955) immune response; (GO:0042493) response to drug
12.20 ADAMTS1 a disintegrin-like and 
metalloprotease (reprolysin 
type) with thrombospondin type 
1 motif, 1
(GO:0008201) heparin binding; (GO:0016787) hydrolase activity; (GO:0005178) integrin binding; 
(GO:0007229) integrin-mediated signaling pathway; (GO:0004222) metalloendopeptidase activity; 
(GO:0008237) metallopeptidase activity; (GO:0008285) negative regulation of cell proliferation; 
(GO:0006508) proteolysis and peptidolysis; (GO:0008270) zinc ion binding
11.99 SPARC secreted protein, acidic, 
cysteine-rich (osteonectin)
(GO:0005509) calcium ion binding; (GO:0005518) collagen binding
11.76 F3 coagulation factor III 
(thromboplastin, tissue factor)
(GO:0007596) blood coagulation; (GO:0003801) blood coagulation factor activity; (GO:0004896) 
hematopoietin/interferon-class (D200-domain) cytokine receptor activity; (GO:0006955) immune 
response; (GO:0004872) receptor activity; (GO:0004888) transmembrane receptor activity
11.71 PLS3 plastin 3 (T isoform) (GO:0003779) actin binding; (GO:0005509) calcium ion binding
11.70 THBS1 thrombospondin 1 (GO:0007596) blood coagulation; (GO:0005509) calcium ion binding; (GO:0007155) cell adhesion; 
(GO:0005194) cell adhesion molecule activity; (GO:0006928) cell motility; (GO:0007275) 
development; (GO:0004866) endopeptidase inhibitor activity; (GO:0008201) heparin binding; 
(GO:0007399) neurogenesis; (GO:0005515) protein binding; (GO:0004871) signal transducer 
activity; (GO:0005198) structural molecule activity
11.69 PLOD2 procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 
(lysine hydroxylase) 2
(GO:0016491) oxidoreductase activity; (GO:0016702) oxidoreductase activity\, acting on single 
donors with incorporation of molecular oxygen\, incorporation of two atoms of oxygen; 
(GO:0008475) procollagen-lysine 5-dioxygenase activity; (GO:0019538) protein metabolism; 
(GO:0006464) protein modification
11.37 CAV1 caveolin 1, caveolae protein, 22 
kDa
(GO:0005198) structural molecule activity; (GO:0008181) tumor suppressor
11.36 gnf1h04130_x_at None NoneBMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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11.28 FN1 fibronectin 1 (GO:0006953) acute-phase response; (GO:0007155) cell adhesion; (GO:0016477) cell migration; 
(GO:0005518) collagen binding; (GO:0005201) extracellular matrix structural constituent; 
(GO:0008201) heparin binding; (GO:0009611) response to wounding
11.18 SMARCA1 SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, subfamily 
a, member 1
(GO:0005524) ATP binding; (GO:0008026) ATP-dependent helicase activity; (GO:0003677) DNA 
binding; (GO:0004002) adenosinetriphosphatase; (GO:0006338) chromatin remodeling; 
(GO:0004386) helicase activity; (GO:0045182) translation regulator activity
11.08 TAGLN transgelin (GO:0007517) Muscle development
10.95 COL4A1 collagen, type IV, alpha 1 (GO:0003677) DNA binding; (GO:0005202) collagen; (GO:0005201) extracellular matrix structural 
constituent; (GO:0006817) phosphate transport
10.90 CAV2 caveolin 2 (GO:0008181) tumor suppressor
10.90 TPM1 tropomyosin 1 (alpha) (GO:0003779) actin binding; (GO:0007517) muscle development; (GO:0008016) regulation of 
heart rate; (GO:0005200) structural constituent of cytoskeleton; (GO:0008307) structural 
constituent of muscle
10.85 GJA1 gap junction protein, alpha 1, 43 
kDa (connexin 43)
(GO:0007267) cell-cell signaling; (GO:0015285) connexon channel activity; (GO:0007507) heart 
development; (GO:0015075) ion transporter activity; (GO:0006936) muscle contraction; 
(GO:0007605) perception of sound; (GO:0043123) positive regulation of I-kappaB kinase/NF-
kappaB cascade; (GO:0004871) signal transducer activity; (GO:0006832) small molecule transport; 
(GO:0006810) transport
10.82 COL1A2 collagen, type I, alpha 2 (GO:0005202) collagen; (GO:0005201) extracellular matrix structural constituent; (GO:0006817) 
phosphate transport; (GO:0001501) skeletal development; (GO:0008147) structural constituent of 
bone
10.61 FXR1 fragile X mental retardation, 
autosomal homolog 1
(GO:0003677) DNA binding; (GO:0003723) RNA binding; (GO:0006915) apoptosis; 
(GO:0003676) nucleic acid binding; (GO:0006913) nucleocytoplasmic transport
10.60 COL6A3 collagen, type VI, alpha 3 cell adhesion (GO:0007155);cell adhesion molecule activity (GO:0005194);collagen 
(GO:0005202);extracellular matrix structural constituent (GO:0005201);muscle development 
(GO:0007517);phosphate transport (GO:0006817);protein binding (GO:0005515);serine-type 
endopeptidase inhibitor activity (GO:0004867)
10.52 CYR61 cysteine-rich, angiogenic inducer, 
61
cell adhesion (GO:0007155);cell proliferation (GO:0008283);chemotaxis 
(GO:0006935);embryogenesis and morphogenesis (GO:0007345);heparin binding 
(GO:0008201);insulin-like growth factor binding (GO:0005520);morphogenesis 
(GO:0009653);regulation of cell growth (GO:0001558)
10.50 10-Sep septin 10 GTP binding (GO:0005525)
10.44 IL1R1 interleukin 1 receptor, type I cell surface receptor linked signal transduction (GO:0007166);immune response 
(GO:0006955);inflammatory response (GO:0006954);interleukin-1 receptor activity 
(GO:0004908);interleukin-1\, Type I\, activating receptor activity (GO:0004909);signal transducer 
activity (GO:0004871);transmembrane receptor activity (GO:0004888)
10.37 WBP5 WW domain binding protein 1 DNA binding (GO:0003677)
10.35 LAMB1 laminin, beta 1 cell adhesion (GO:0007155);cell adhesion molecule activity (GO:0005194);protein binding 
(GO:0005515);structural molecule activity (GO:0005198)
10.33 EMP1 epithelial membrane protein 1 cell death (GO:0008219);cell growth (GO:0016049);cell proliferation (GO:0008283);development 
(GO:0007275);oncogenesis (GO:0007048)
10.23 NRP1 neuropilin 1 axon guidance (GO:0007411);cell adhesion (GO:0007155);cell-cell signaling 
(GO:0007267);histogenesis and organogenesis (GO:0007397);neurogenesis 
(GO:0007399);organogenesis (GO:0009887);positive regulation of cell proliferation 
(GO:0008284);receptor activity (GO:0004872);signal transduction (GO:0007165);vascular 
endothelial growth factor receptor activity (GO:0005021)
10.12 COL3A1 collagen, type III, alpha 1 (Ehlers-
Danlos syndrome type IV, 
autosomal dominant)
circulation (GO:0008015);collagen (GO:0005202);extracellular matrix structural constituent 
(GO:0005201);histogenesis and organogenesis (GO:0007397);organogenesis 
(GO:0009887);phosphate transport (GO:0006817)
10.10 CALD1 caldesmon 1 actin binding (GO:0003779);calmodulin binding (GO:0005516);muscle contraction 
(GO:0006936);muscle development (GO:0007517);myosin binding (GO:0017022);tropomyosin 
binding (GO:0005523)
10.10 THBS1 thrombospondin 1 blood coagulation (GO:0007596);calcium ion binding (GO:0005509);cell adhesion 
(GO:0007155);cell adhesion molecule activity (GO:0005194);cell motility 
(GO:0006928);development (GO:0007275);endopeptidase inhibitor activity (GO:0004866);heparin 
binding (GO:0008201);neurogenesis (GO:0007399);protein binding (GO:0005515);signal 
transducer activity (GO:0004871);structural molecule activity (GO:0005198)
10.05 FN1 fibronectin 1 acute-phase response (GO:0006953);cell adhesion (GO:0007155);cell migration 
(GO:0016477);collagen binding (GO:0005518);extracellular matrix structural constituent 
(GO:0005201);heparin binding (GO:0008201);response to wounding (GO:0009611)
10.03 SPARC secreted protein, acidic, 
cysteine-rich (osteonectin)
calcium ion binding (GO:0005509);collagen binding (GO:0005518)
10.02 IGFBP7 insulin-like growth factor binding 
protein 7
insulin-like growth factor binding (GO:0005520);negative regulation of cell proliferation 
(GO:0008285);regulation of cell growth (GO:0001558)
9.99 IL6ST interleukin 6 signal transducer 
(gp130, oncostatin M receptor)
cell surface receptor linked signal transduction (GO:0007166);gp130 (GO:0004898);immune 
response (GO:0006955);interleukin-6 receptor activity (GO:0004915);oncostatin-M receptor 
activity (GO:0004924);receptor activity (GO:0004872);signal transduction (GO:0007165)
9.98 LAMB1 laminin, beta 1 cell adhesion (GO:0007155);cell adhesion molecule activity (GO:0005194);protein binding 
(GO:0005515);structural molecule activity (GO:0005198)
9.94 TAZ transcriptional co-activator with 
PDZ-binding motif (TAZ)
transcription coactivator activity (GO:0003713)
9.93 DCN decorin chondroitin sulfate/dermatan sulfate proteoglycan (GO:0005205);histogenesis and organogenesis 
(GO:0007397);organogenesis (GO:0009887)
9.93 ANXA1 annexin A1 calcium ion binding (GO:0005509);calcium-dependent phospholipid binding (GO:0005544);cell 
motility (GO:0006928);cell surface receptor linked signal transduction (GO:0007166);inflammatory 
response (GO:0006954);lipid metabolism (GO:0006629);phospholipase A2 inhibitor activity 
(GO:0019834);phospholipase inhibitor activity (GO:0004859);phospholipid binding 
(GO:0005543);receptor binding (GO:0005102)
Table 2: PC7 High Extreme Genes. Detailed info for (n = 88) extreme genes in PC7 set H7, ordered most extreme first, including 
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9.89 MYH11 myosin, heavy polypeptide 11, 
smooth muscle
ATP binding (GO:0005524);actin binding (GO:0003779);calmodulin binding (GO:0005516);cell 
growth and/or maintenance (GO:0008151);motor activity (GO:0003774);muscle development 
(GO:0007517);protein amino acid alkylation (GO:0008213);striated muscle contraction 
(GO:0006941)
9.89 EFEMP1 EGF-containing fibulin-like 
extracellular matrix protein 1
calcium ion binding (GO:0005509);visual perception (GO:0007601)
9.88 SPUVE protease, serine, 23 chymotrypsin activity (GO:0004263);hydrolase activity (GO:0016787);proteolysis and peptidolysis 
(GO:0006508);trypsin activity (GO:0004295)
9.87 Hs.514018 CDNA: FLJ22209 fis, clone 
HRC01496
None
9.80 FN1 fibronectin 1 acute-phase response (GO:0006953);cell adhesion (GO:0007155);cell migration 
(GO:0016477);collagen binding (GO:0005518);extracellular matrix structural constituent 
(GO:0005201);heparin binding (GO:0008201);response to wounding (GO:0009611)
9.77 COL16A1 collagen, type XVI, alpha 1 cell adhesion (GO:0007155);collagen (GO:0005202);extracellular matrix structural constituent 
(GO:0005201);phosphate transport (GO:0006817);pregnancy (GO:0007565)
9.73 SNX7 sorting nexin 7 intracellular protein transport (GO:0006886);intracellular signaling cascade (GO:0007242);protein 
transporter activity (GO:0008565)
9.69 AHR aryl hydrocarbon receptor DNA binding (GO:0003677);apoptosis (GO:0006915);ligand-dependent nuclear receptor activity 
(GO:0004879);response to stress (GO:0006950);response to xenobiotic stimulus 
(GO:0009410);signal transduction (GO:0007165);transcription factor activity 
(GO:0003700);transcription from Pol II promoter (GO:0006366)
9.57 COL6A1 collagen, type VI, alpha 1 DNA binding (GO:0003677);cell adhesion (GO:0007155);cell adhesion molecule activity 
(GO:0005194);collagen (GO:0005202);extracellular matrix structural constituent 
(GO:0005201);histogenesis and organogenesis (GO:0007397);molecular_function unknown 
(GO:0005554);phosphate transport (GO:0006817);protein binding (GO:0005515)
9.55 KIAA0992 palladin amino acid metabolism (GO:0006520)
9.54 COL5A2 collagen, type V, alpha 2 cell growth and/or maintenance (GO:0008151);collagen (GO:0005202);extracellular matrix 
glycoprotein (GO:0005207);extracellular matrix structural constituent (GO:0005201);phosphate 
transport (GO:0006817)
9.53 FBN1 fibrillin 1 (Marfan syndrome) calcium ion binding (GO:0005509);development (GO:0007275);extracellular matrix structural 
constituent (GO:0005201);skeletal development (GO:0001501);visual perception (GO:0007601)
9.51 PAM peptidylglycine alpha-amidating 
monooxygenase
electron transporter activity (GO:0005489);monooxygenase activity (GO:0004497);peptide 
amidation (GO:0001519);peptidylglycine monooxygenase activity (GO:0004504);protein 
modification (GO:0006464)
9.50 LOC92912 hypothetical protein LOC92912 ligase activity (GO:0016874);ubiquitin conjugating enzyme activity (GO:0004840);ubiquitin cycle 
(GO:0006512);ubiquitin-protein ligase activity (GO:0004842)
9.47 COL6A2 collagen, type VI, alpha 2 cell-cell adhesion (GO:0016337);collagen (GO:0005202);extracellular matrix organization and 
biogenesis (GO:0030198);extracellular matrix structural constituent (GO:0005201);muscle 
development (GO:0007517);phosphate transport (GO:0006817);protein binding, bridging 
(GO:0030674)
9.45 PTX1 PTX1 protein None
9.41 KIAA0992 palladin amino acid metabolism (GO:0006520)
9.33 CSPG2 chondroitin sulfate proteoglycan 
2 (versican)
calcium ion binding (GO:0005509);cell adhesion (GO:0007155);chondroitin sulfate proteoglycan 
(GO:0005204);development (GO:0007275);glycosaminoglycan binding (GO:0005539);heterophilic 
cell adhesion (GO:0007157);hyaluronic acid binding (GO:0005540);lectin 
(GO:0005530);proteoglycan (GO:0005203);sugar binding (GO:0005529)
9.32 CSPG2 chondroitin sulfate proteoglycan 
2 (versican)
calcium ion binding (GO:0005509);cell adhesion (GO:0007155);chondroitin sulfate proteoglycan 
(GO:0005204);development (GO:0007275);glycosaminoglycan binding (GO:0005539);heterophilic 
cell adhesion (GO:0007157);hyaluronic acid binding (GO:0005540);lectin 
(GO:0005530);proteoglycan (GO:0005203);sugar binding (GO:0005529)
9.30 SERPINH1 serine (or cysteine) proteinase 
inhibitor, clade H (heat shock 
protein 47), member 1, (collagen 
binding protein 1)
collagen binding (GO:0005518);heat shock protein activity (GO:0003773);response to stress 
(GO:0006950);serine-type endopeptidase inhibitor activity (GO:0004867);serpin (GO:0004868)
9.23 TM4SF6 transmembrane 4 superfamily 
member 6
cell adhesion molecule activity (GO:0005194);cell motility (GO:0006928);positive regulation of I-
kappaB kinase/NF-kappaB cascade (GO:0043123);signal transducer activity (GO:0004871)
9.20 PTRF polymerase I and transcript 
release factor
None
9.19 LATS2 LATS, large tumor suppressor, 
homolog 2 (Drosophila)
ATP binding (GO:0005524);protein amino acid phosphorylation (GO:0006468);protein serine/
threonine kinase activity (GO:0004674);transferase activity (GO:0016740);tumor suppressor 
(GO:0008181)
9.12 CTBP2 C-terminal binding protein 2 L-serine biosynthesis (GO:0006564);negative regulation of cell proliferation 
(GO:0008285);oxidoreductase activity (GO:0016491);oxidoreductase activity, acting on the CH-
OH group of donors, NAD or NADP as acceptor (GO:0016616);tumor suppressor 
(GO:0008181);viral replication (GO:0008166)
9.06 ITGAV integrin, alpha V (vitronectin 
receptor, alpha polypeptide, 
antigen CD51)
cell adhesion (GO:0007155);cell adhesion receptor activity (GO:0004895);cell-matrix adhesion 
(GO:0007160);integrin-mediated signaling pathway (GO:0007229);protein binding (GO:0005515)
9.05 RCN2 reticulocalbin 2, EF-hand calcium 
binding domain
calcium ion binding (GO:0005509);protein binding (GO:0005515);tumor suppressor (GO:0008181)
8.98 CPD carboxypeptidase D carboxypeptidase A activity (GO:0004182);carboxypeptidase D activity 
(GO:0004187);carboxypeptidase activity (GO:0004180);hydrolase activity 
(GO:0016787);proteolysis and peptidolysis (GO:0006508);zinc ion binding (GO:0008270)
8.98 FLJ21174 hypothetical protein FLJ21174 None
8.96 MGC5395 hypothetical protein MGC5395 intracellular signaling cascade (GO:0007242);neurogenesis (GO:0007399);protein binding 
(GO:0005515)
8.96 MFAP2 microfibrillar-associated protein 
2
extracellular matrix glycoprotein (GO:0005207);extracellular matrix structural constituent 
(GO:0005201)
Table 2: PC7 High Extreme Genes. Detailed info for (n = 88) extreme genes in PC7 set H7, ordered most extreme first, including 
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8.94 CRIM1 cysteine-rich motor neuron 1 cysteine-type endopeptidase activity (GO:0004197);insulin-like growth factor binding 
(GO:0005520);insulin-like growth factor receptor activity (GO:0005010);neurogenesis 
(GO:0007399);proteolysis and peptidolysis (GO:0006508);regulation of cell growth 
(GO:0001558);serine-type endopeptidase inhibitor activity (GO:0004867)
8.92 ALDH1A3 aldehyde dehydrogenase 1 family, 
member A3
alcohol metabolism (GO:0006066);aldehyde dehydrogenase [NAD(P)+] activity 
(GO:0004030);aldehyde dehydrogenase activity (GO:0004028);lipid metabolism 
(GO:0006629);metabolism (GO:0008152);oxidoreductase activity (GO:0016491)
8.92 MGC34132 hypothetical protein MGC34132 None
Table 2: PC7 High Extreme Genes. Detailed info for (n = 88) extreme genes in PC7 set H7, ordered most extreme first, including 
common name, description, and associated Gene Ontology terms (provided with the GNF dataset). These extreme genes are shown 
as red points in Figure 1. (Continued)BMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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ples. Tissue samples were skeletal muscle biopsies from 3
diagnosis groups: normal glucose tolerance (NGT, n  =
17); impaired glucose tolerance (IGT, n = 8); and Type 2
diabetes mellitus (DM2, n = 18). We used our PCA inter-
pretation software to perform an unsupervised analysis of
the DM2 vs. NGT subset (as that subset is comparable to
the previous published result). As described in the Meth-
odology section, PCEG sets were determined using an
extremeThresh  likelihood threshold of 0.001, which
yielded about 50 high and 50 low extreme genes per prin-
cipal component. For each principal component N, sam-
ples were partitioned in to UPN,  FLATN  and  DOWNN
sample sets on the basis of PC-N  extreme high and
extreme low expression differences. The supplemental
materials contain PCA interpretation results for all 35
principal components, as well as results of a comparable
analysis done at extremeThresh  = 0.0001 which yielded
smaller PCEG sets (see [35]).
This dataset contains more than 50 covariates, which pro-
vides the opportunity to interpret each principal compo-
nent by searching for covariates that correlate well with
expression patterns in the PCEG sets. As described in the
Methodology section, we asked if any of the covariate
annotations are well correlated with the partitioning of
samples into UPN, FLATN and DOWNN sets. Covariate dis-
tributions were compared across different partitions
(when sufficient data was available) and any significant
trends identified were recorded (see Table 7). For covari-
ates identified as significantly correlated with a principal
component's sample partitioning, covariate distribution
plots were generated to further investigate and evaluate
the apparent relationship. For example, Figure 5 illustrates
that PC14's UP14, FLAT14 and DOWN14 sample partitions
appear to be significantly related to two covariate meas-
urements: Insulin_0 (sig = 0.0010); and Type2b_(%) (sig=
0.0077). The Pearson's correlation between the mean
expression for the PC14EG-high set and Insulin_0 and
Type2b_(%) covariates are r = 0.411 and r = 0.467 respec-
tively.
Discussion
This PCA-based data-mining tool highlights specific pat-
terns of expression and associates them in a convenient
way with the genes and samples responsible for those pat-
terns. Some associations in the first few principal compo-
nents (PCs) of the GNF set reflect major features in the
data that are expected. This includes the global high and
low constitutive expression profiles of PC1 (67% of vari-
ance in the GNF dataset). A component similar to this is
often the first or second PC in Affymetrix array datasets.
GNF PC3, in contrast, highlighted brain/neuronal tissues,
which we expected in this dataset because there are many
more samples from brain regions than from any other tis-
sue, and there are thousands of genes that are expressed in
Table 3: PC7 Tissue Partitioning and Ordering. Partitioning and 
ordering of tissues into sets UP7(n = 51) and DOWN7(n = 48) sets 
found to have significant expression differences for H7 and L7 at 
test1Thresh = 0.05. Tissues within groups are ordered by 
decreasing abs (mean (H7)–mean(L7)), which has the effect of 
placing the most significantly affected tissues at the top of each 
list. The most significant tissues in UP7 are at the left of Figure 2, 
and the most significant conditions in DOWN7 are at the right of 
Figure 2.
UP7 DOWN7
SmoothMuscle PB-CD19+Bcells
SmoothMuscle PB-CD19+Bcells
CardiacMyocytes PB-BDCA4+Dentritic_Cells
ADIPOCYTE PB-BDCA4+Dentritic_Cells
ADIPOCYTE lymphomaburkittsRaji
CardiacMyocytes lymphomaburkittsDaudi
TestisGermCell lymphomaburkittsDaudi
bronchialepithelialcells lymphomaburkittsRaji
bronchialepithelialcells PB-CD56+NKCells
PLACENTA bonemarrow
PLACENTA bonemarrow
TestisInterstitial PB-CD56+NKCells
UterusCorpus leukemiapromyelocytic(hl60)
Uterus 721_B_lymphoblasts
FetalThyroid Tonsil
OlfactoryBulb Tonsil
TestisLeydigCell WHOLEBLOOD
UterusCorpus 721_B_lymphoblasts
FetalThyroid leukemiapromyelocytic(hl60)
atrioventricularnode WHOLEBLOOD
TestisInterstitial thymus
TestisLeydigCell PB-CD8+Tcells
TestisSeminiferousTubule PB-CD8+Tcells
atrioventricularnode thymus
DRG lymphnode
Fetallung Heart
Uterus lymphnode
Ciliaryganglion PB-CD14+Monocytes
TestisGermCell PB-CD4+Tcells
AdrenalCortex PB-CD4+Tcells
Fetallung PB-CD14+Monocytes
Ciliaryganglion BM-CD71+EarlyErythroid
DRG BM-CD34+
TONGUE Liver
SuperiorCervicalGanglion Heart
Ovary BM-CD71+EarlyErythroid
TestisSeminiferousTubule BM-CD34+
Skin BM-CD105+Endothelial
OlfactoryBulb salivarygland
TONGUE leukemialymphoblastic(molt4)
Ovary Liver
TrigeminalGanglion Lung
AdrenalCortex Lung
PancreaticIslets leukemialymphoblastic(molt4)
Skin BM-CD105+Endothelial
Fetalbrain BM-CD33+Myeloid
TrigeminalGanglion salivarygland
Fetalbrain BM-CD33+Myeloid
Amygdala
SuperiorCervicalGanglion
PrefrontalCortexBMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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Table 4: PC21 Low Extreme Genes. Detailed info for (n = 49) extreme genes in PC21 set L21, ordered most extreme first, including 
common name, description, and associated Gene Ontology terms (provided with the GNF dataset). These extreme genes are shown 
as blue points in Figure 3.
PC-21 Value Name Description Function
-11.74 Ckm creatine kinase, muscle creatine kinase activity (GO:0004111); transferase activity, transferring phosphorus-
containing groups (GO:0016772)
-11.61 ACTA1 actin, alpha 1, skeletal muscle motor activity (GO:0003774);muscle contraction (GO:0006936);muscle 
development (GO:0007517);structural constituent of cytoskeleton (GO:0005200)
-10.27 MYH7 myosin, heavy polypeptide 7, cardiac 
muscle, beta
ATP binding (GO:0005524);actin binding (GO:0003779);calmodulin binding 
(GO:0005516);microfilament motor activity (GO:0000146);motor activity 
(GO:0003774);muscle contraction (GO:0006936);muscle development 
(GO:0007517);protein amino acid alkylation (GO:0008213);striated muscle 
contraction (GO:0006941);structural constituent of muscle (GO:0008307)
-10.01 TPM1 tropomyosin 1 (alpha) actin binding (GO:0003779);muscle development (GO:0007517);regulation of heart 
rate (GO:0008016);structural constituent of cytoskeleton (GO:0005200);structural 
constituent of muscle (GO:0008307)
-9.10 MYL1 myosin, light polypeptide 1, alkali; skeletal, 
fast
calcium ion binding (GO:0005509);muscle development (GO:0007517);structural 
constituent of muscle (GO:0008307)
-9.10 TNNC1 troponin C, slow calcium ion binding (GO:0005509);muscle development (GO:0007517)
-8.92 PPP1R1A protein phosphatase 1, regulatory 
(inhibitor) subunit 1A
glycogen metabolism (GO:0005977);protein phosphatase inhibitor activity 
(GO:0004864);signal transduction (GO:0007165);type 1 serine/threonine specific 
protein phosphatase inhibitor activity (GO:0004865)
-8.79 TNNC2 troponin C2, fast calcium ion binding (GO:0005509);muscle development (GO:0007517)
-8.71 TNNT1 troponin T1, skeletal, slow muscle development (GO:0007517);tropomyosin binding (GO:0005523)
-8.70 KRT14 keratin 14 (epidermolysis bullosa simplex, 
Dowling-Meara, Koebner)
biological_process unknown (GO:0000004);structural constituent of cytoskeleton 
(GO:0005200);structural constituent of epidermis (GO:0030280)
-8.67 TTID titin immunoglobulin domain protein 
(myotilin)
muscle contraction (GO:0006936);protein binding- (GO:0005515);structural 
constituent of muscle (GO:0008307)
-8.49 HUMMLC2B myosin light chain 2 calcium ion binding (GO:0005509);structural constituent of muscle (GO:0008307)
-8.35 TRIM T-cell receptor interacting molecule DNA binding (GO:0003677);cellular defense response (GO:0006968);signal 
transduction (GO:0007165);transmembrane receptor protein tyrosine kinase 
adaptor protein activity (GO:0005068)
-8.20 TTN titin ATP binding (GO:0005524);calmodulin binding (GO:0005516);cation transporter 
activity (GO:0008324);hematopoietin/interferon-class (D200-domain) cytokine 
receptor activity (GO:0004896);muscle development (GO:0007517);myosin binding 
(GO:0017022);protein amino acid phosphorylation (GO:0006468);protein serine/
threonine kinase activity (GO:0004674);regulation of actin filament length 
(GO:0030832);somatic muscle development (GO:0007525);striated muscle 
contraction (GO:0006941);structural constituent of muscle 
(GO:0008307);structural molecule activity (GO:0005198);transferase activity 
(GO:0016740)
-7.91 CSRP3 cysteine and glycine-rich protein 3 (cardiac 
LIM protein)
None
-7.66 MB myoglobin electron transporter activity (GO:0005489);globin (GO:0001524);oxygen transport 
(GO:0015671);oxygen transporter activity (GO:0005344);transport (GO:0006810)
-7.46 ENO3 enolase 3, (beta, muscle) glycolysis (GO:0006096);lyase activity (GO:0016829);magnesium ion binding 
(GO:0000287);phosphopyruvate hydratase activity (GO:0004634)
-7.32 NTRK2 neurotrophic tyrosine kinase, receptor, 
type 2
ATP binding (GO:0005524);kinase activity (GO:0016301);neurogenesis 
(GO:0007399);neurotrophin TRKB receptor activity (GO:0005015);neurotrophin 
binding (GO:0043121);protein amino acid phosphorylation (GO:0006468);receptor 
activity (GO:0004872);transferase activity (GO:0016740);transmembrane receptor 
protein tyrosine kinase activity (GO:0004714);transmembrane receptor protein 
tyrosine kinase signaling pathway (GO:0007169)
-7.28 MYL2 myosin, light polypeptide 2, regulatory, 
cardiac, slow
calcium ion binding (GO:0005509);muscle development (GO:0007517);structural 
constituent of muscle (GO:0008307)
-7.27 TF Transferring ferric iron binding (GO:0008199);iron ion binding (GO:0005506);iron ion 
homeostasis (GO:0006879);iron ion transport (GO:0006826);transport 
(GO:0006810)
-7.16 ACSL1 acyl-CoA synthetase long-chain family 
member 1
digestion (GO:0007586);fatty acid metabolism (GO:0006631);ligase activity 
(GO:0016874);long-chain-fatty-acid-CoA ligase activity (GO:0004467);magnesium 
ion binding (GO:0000287);metabolism (GO:0008152)
-7.10 MYBPC1 myosin binding protein C, slow type actin binding (GO:0003779);cell adhesion (GO:0007155);cell adhesion molecule 
activity (GO:0005194);muscle development (GO:0007517);protein binding 
(GO:0005515);striated muscle contraction (GO:0006941);structural constituent of 
muscle (GO:0008307)
-7.07 S100A2 S100 calcium binding protein A2 biological_process unknown (GO:0000004);calcium ion binding (GO:0005509)
-7.07 PYGM phosphorylase, glycogen; muscle (McArdle 
syndrome, glycogen storage disease type 
V)
amino acid metabolism (GO:0006520);carbohydrate metabolism 
(GO:0005975);glycogen metabolism (GO:0005977);glycogen phosphorylase activity 
(GO:0008184);transferase activity, transferring glycosyl groups (GO:0016757)
-6.99 ACTN2 actinin, alpha 2 actin binding (GO:0003779);calcium ion binding (GO:0005509);protein binding 
(GO:0005515);structural constituent of muscle (GO:0008307)
-6.76 MYBPC2 myosin binding protein C, fast type actin binding (GO:0003779);cell adhesion (GO:0007155);cell adhesion molecule 
activity (GO:0005194);muscle development (GO:0007517);protein binding 
(GO:0005515);striated muscle contraction (GO:0006941);structural constituent of 
muscle (GO:0008307)BMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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-6.71 UCP2 uncoupling protein 2 (mitochondrial, 
proton carrier)
binding (GO:0005488);mitochondrial transport (GO:0006839);proton transport 
(GO:0015992);small molecule transport (GO:0006832);transport 
(GO:0006810);transporter activity (GO:0005215);uncoupling protein activity 
(GO:0015302)
-6.63 NEB nebulin actin binding (GO:0003779);muscle development (GO:0007517);regulation of actin 
filament length (GO:0030832);somatic muscle development 
(GO:0007525);structural constituent of muscle (GO:0008307)
-6.60 IDH2 isocitrate dehydrogenase 2 (NADP+), 
mitochondrial
carbohydrate metabolism (GO:0005975);glyoxylate cycle (GO:0006097);isocitrate 
dehydrogenase (NADP+) activity (GO:0004450);main pathways of carbohydrate 
metabolism (GO:0006092);metabolism (GO:0008152);oxidoreductase activity 
(GO:0016491);tricarboxylic acid cycle (GO:0006099)
-6.47 CSTA cystatin A (stefin A) cysteine protease inhibitor activity (GO:0004869);endopeptidase inhibitor activity 
(GO:0004866)
-6.45 MYH2 myosin, heavy polypeptide 2, skeletal 
muscle, adult
ATP binding (GO:0005524);actin binding (GO:0003779);calmodulin binding 
(GO:0005516);microfilament motor activity (GO:0000146);motor activity 
(GO:0003774);muscle contraction (GO:0006936);muscle development 
(GO:0007517);muscle motor activity (GO:0003776);protein amino acid alkylation 
(GO:0008213);striated muscle contraction (GO:0006941)
-6.42 KRT4 keratin 4 cytoskeleton organization and biogenesis (GO:0007010);structural constituent of 
cytoskeleton (GO:0005200);structural molecule activity (GO:0005198)
-6.40 CLIC6 chloride intracellular channel 6 chloride transport (GO:0006821);ion transport (GO:0006811);voltage-gated 
chloride channel activity (GO:0005247)
-6.27 SPRR1A small proline-rich protein 1A structural molecule activity (GO:0005198)
-6.25 TNNI2 troponin I, skeletal, fast actin binding (GO:0003779);muscle development (GO:0007517)
-6.22 TNNI1 troponin I, skeletal, slow actin binding (GO:0003779);muscle development (GO:0007517);tropomyosin 
binding (GO:0005523)
-6.17 LDB3 LIM domain binding 3 electron transport (GO:0006118);electron transporter activity 
(GO:0005489);protein binding (GO:0005515)
-6.14 CRYAB crystallin, alpha B chaperone activity (GO:0003754);muscle contraction (GO:0006936);protein folding 
(GO:0006457);structural constituent of eye lens (GO:0005212);visual perception 
(GO:0007601)
-6.12 HFL1 H factor (complement)-like 1 plasma protein (GO:0005209)
-6.15 S100A1 S100 calcium binding protein A1 calcium ion binding (GO:0005509);cell communication (GO:0007154);intracellular 
signaling cascade (GO:0007242);neurogenesis (GO:0007399);protein binding 
(GO:0005515);zinc ion binding (GO:0008270)
-6.09 HSPB8 heat shock 22 kDa protein 8 biological_process unknown (GO:0000004);heat shock protein activity 
(GO:0003773);protein serine/threonine kinase activity (GO:0004674);transferase 
activity (GO:0016740)
-5.93 PPFIBP2 PTPRF interacting protein, binding protein 
2 (liprin beta 2)
None
-5.88 GHR growth hormone receptor endocytosis (GO:0006897);growth hormone receptor activity 
(GO:0004903);growth pattern (GO:0007150);receptor activity 
(GO:0004872);skeletal development (GO:0001501)
-5.85 ACSL1 acyl-CoA synthetase long-chain family 
member 1
digestion (GO:0007586);fatty acid metabolism (GO:0006631);ligase activity 
(GO:0016874);long-chain-fatty-acid-CoA ligase activity (GO:0004467);magnesium 
ion binding (GO:0000287);metabolism (GO:0008152)
-5.84 MGC42493 hypothetical protein MGC42493 nucleic acid binding (GO:0003676);zinc ion binding (GO:0008270)
-5.73 SCD stearoyl-CoA desaturase (delta-9-
desaturase)
fatty acid biosynthesis (GO:0006633);iron ion binding 
(GO:0005506);oxidoreductase activity (GO:0016491);stearoyl-CoA 9-desaturase 
activity (GO:0004768)
-5.67 hIAN2 human immune associated nucleotide 2 GTP binding (GO:0005525)
-5.65 PDE4DIP phosphodiesterase 4D interacting protein 
(myomegalin)
None
-5.63 HBA2 hemoglobin, alpha 2 oxygen transport (GO:0015671);oxygen transporter activity (GO:0005344);protein 
binding (GO:0005515);transport (GO:0006810)
Table 4: PC21 Low Extreme Genes. Detailed info for (n = 49) extreme genes in PC21 set L21, ordered most extreme first, including 
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a general brain pattern. The GO enrichment analysis asso-
ciated with PC3lowEGs confirmed this impression by
identifying neurogenesis, central nervous system, and syn-
aptic terms as significantly enriched for PC3EG (Table 6).
We asked if principal components that account individu-
ally for small fractions of variation in the data are likely to
be significant. Conventional practice generally ignores
principal components accounting for a few percent, or
less, of total variation, on the assumption that such minor
components are most likely dominated by noise. We
believe this assumption, that all of the PC's accounting for
small fractions of data should be ignored because they are
artefact, to be wrong in the context of our analysis. We
believe this, in part, because in our analysis we find many
PCEGs for minor components are statistically enriched
(Table 6). Further, computational experiments using ran-
domized data fail to produce any significant enrichments.
This GO enrichment analysis, it should be noted, tends to
underestimate the fraction of gene sets that are significant.
This is a known artefact in instances where the input gene
number (here those passing the selected rank sum thresh-
old) is small, and its effects are exacerbated by the fact that
GO annotations for human are still very much in a build-
ing phase. Many genes that will eventually be associated
with GO terms are not yet entered. This means that reduc-
ing the threshold modestly, and therefore increasing the
gene number, can uncover additional significant GO term
enrichment in some of these PCs. For complete results of
GNF analysis at p < = 0.001 see our supplemental materi-
als web site [35].
Viewed from a biological perspective, this PCA mining
revealed several different classes of relationships. GNF
PC21 is a good example of a component that highlights a
coherent gene set and its corresponding tissues, many of
which would also be grouped together by conventional
clustering algorithms. This is true even though PC21
accounts for just 0.25% of total variation. The PC21EG-
low set (defined at p < = 0.00001) was enriched in a statis-
tically significant way for five different GO terms (Table
6), and these terms (myogenesis, muscle contraction, etc.)
tell a simple and internally consistent story about muscle
development and function. The top tissue samples driving
PC21-low are skeletal muscle, tongue (also composed
largely of striated muscle), heart and thyroid (which
includes a population of myoid cells). Most top-ranked
genes in this PCEG set are so specific for striated muscle
that they would also appear together in conventional clus-
terings, although many clustering approaches become
technically problematic with datasets of this size. How-
GNF PC7 High and Low Extreme Gene Probes Figure 1
GNF PC7 High and Low Extreme Gene Probes. Scat-
ter plot of N = 33689 probe expression levels projected 
onto PC6 vs. PC7 space with high and low extreme gene sets 
H7 (red points, n = 88) and L7 (blue points, n = 20); extreme 
genes selected at extremeThresh = 0.00001. The extreme 
genes in H7 are listed in Table 2.
Table 5: PC21 Tissue Partitioning and Ordering. Partitioning and 
ordering of tissues into sets UP21(n = 8) and DOWN21 (n = 20) sets 
found to have significant expression differences for H21 and L21 at 
test1Thresh = 0.05. Tissues within groups are ordered by 
decreasing abs(mean (H21)–mean(L21)), which has the effect of 
placing the most significantly affected tissues at the top of each 
list. The most significant tissues in UP21 are at the left of Figure 4, 
and the most significant conditions in DOWN21 are at the right of 
Figure 4.
UP21 DOWN21
Pancreas TONGUE
Pancreas SkeletalMuscle
PancreaticIslets TONGUE
PancreaticIslets SkeletalMuscle
Bonemarrow Thyroid
Bonemarrow Heart
BM-CD34+ Thyroid
BM-CD34+ FetalThyroid
Heart
FetalThyroid
Testis
721_B_lymphoblasts
Testis
ADIPOCYTE
721_B_lymphoblasts
ADIPOCYTE
Thalamus
Caudatenucleus
Spinalcord
ProstateBMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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ever the PC21EG-low list differs from a conventional mus-
cle cluster because it also includes some genes that are
partly associated with muscle and partly associated with
other tissues. PP1R1A, a regulatory subunit of protein
phosphatase1, is such a gene. A role for it in striated mus-
cle is suggested based on its coherent presence in tongue,
skeletal and cardiac samples, even though it might well
not have been seen in this light by standard clustering.
The second example is GNF PC7, which accounts for
0.81% of variation. It illustrates a different kind of biolog-
ical relationship that more strongly distinguishes results
of PCA mining from classical clustering. Top extreme
genes associated with PC7 by inspection turn out to be a
"who's who" of extracellular matrix components (a spe-
cific subset of fibronectins, collagens, laminins plus
matrix associated proteins like MFAP5, MGP, LUM; regu-
latory molecules that mediate stability and function of
those matrix components (thrombospondin, SPARC,
ADAMTS1, Plod2); and matrix associated signalling and
matrix associated signal modulators (insulin like growth
factor binding proteins 7, 8 and 10; Sema3c). GO analysis
confirms what inspection of the top PC7EGs suggested:
namely that a set of extracellular matrix components are
expressed in these driving tissues. It is instructive to look
at the individual expression profiles for these genes
directly at the GNF website and also in aggregate, as repre-
sented in the tissue (conditions) list in Table 2. The most
prominent contributing tissues associated with high
expression of these genes are informative specifically
because they do not constitute a group that would have
been selected a priori as a coherent set based on known tis-
sue function or shared developmental origin.
This is useful because a biologist interrogating the GNF
database would not likely have constructed a query com-
bining adipocytes, smooth muscle, bronchial epithelium,
nor would one expect traditional clustering algorithms to
place these genes so close to each other as to catalyze the
same observation. Similarly, conventional ordering algo-
rithms would not have placed them adjacent to each other
because other parts of their expression profiles, contain-
ing different genes than those in PC7, would dominate
their positions. And concerning genes, they have, in addi-
tion to commonalities of expression highlighted by PC7,
differences from each other in additional diverse tissues
not highlighted by PC7. The PCA grouping gives impetus
and a necessary starting gene list to search for one or more
factors or regulatory RNAs with a similar expression pat-
tern, or to search for a shared and perhaps evolutionarily
conserved cis-acting DNA sequence motifs. It is unlikely
that these working hypotheses would have been arrived at
easily by widely used methods of gene expression analy-
sis.
GNF PC21 High and Low Extreme Gene Probes Figure 3
GNF PC21 High and Low Extreme Gene Probes. 
Scatter plot of N = 33689 probe expression levels projected 
onto PC20 vs. PC21 space with high and low extreme gene 
sets H21 (red points, n = 37) and L21 (blue points, n = 49); 
extreme genes selected at extremeThresh = 0.00001. The 
extreme genes in L21 are listed in Table 4.
GNF PC7 Extreme Gene Trajectory Plot with Tissues  Ordered by Significance Figure 2
GNF PC7 Extreme Gene Trajectory Plot with Tis-
sues Ordered by Significance. Trajectory plots for high 
and low extreme gene sets H7 (red, n = 88) and L7 (blue, n = 
20) with tissues ordered by decreasing mean(H7) – mean(L7), 
and thus grouped by significance (UP7 group at left, FLAT7 
group in middle and LOW7 group at right) at test1Thresh = 
0.05. Table 3 lists the tissues within UP7 and DOWN7 that 
occur at each end of this plot.BMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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The diabetes dataset offered us an opportunity to add
more value to principal component interpretations by
searching for covariates that appear correlated at some sig-
nificance level. The relationships highlighted between
covariates and principal components are suggestive, but
not conclusive by themselves. Rather, they provide
hypotheses that a researcher may wish to further investi-
gate. While we have not delved deeply into this dataset,
we believe that a number of the principal components are
highlighting a number of meaningful sources of variation
present. It is not clear whether this set should exhibit the
same proportion of meaningful principal components as
the GNF dataset, as by design the NGT vs. GM2 dataset
does not contain substantial diversity of samples. Like-
wise, the selection of covariates was focused on a narrow
set of measurements selected to be indicative of diabetes
status, and so many covariates are redundant. We antici-
pate this tool will be maximally useful in cases where
datasets are rich in both sample complexity and diversity
of covariates.
Conclusion
Results presented above show that this PCA-mining
approach can guide a user to biologically significant
observations that both complement and reinforce those
from conventional clustering analysis. The software pack-
age and web interface make this style of microarray anal-
ysis straightforward and accessible.
We have applied this to four additional microarray data-
sets (as yet unpublished) and to one multi-spectral imag-
ing dataset. In each case we found the interpretations that
the tool presented to be useful. In general, it seems that
the top few principal components identify very broad
characteristics of the data. Digging to the deeper compo-
nents that comprise smaller but more particular substruc-
ture in the data leads to more subtle but often meaningful
observations, many being complementary to standard
clustering.
With respect to the top few components, PC1 is usually
the approximate diagonal through the sample/condition
space, explaining the overall variation in absolute expres-
sion level. For some other datasets we have noticed that
the top few PCs can also highlight effects of preprocessing
normalization steps or global data quality issues. This
means they do not necessarily expose the most important
biological variation. Thus, in one microarray dataset not
shown here, PC2 was found to be extremely well corre-
lated with a measure of quality of samples, as reflected by
the percent of Affymetrix probes called present. Given this
evidence of data quality effects comprising a major source
of variation over the entire dataset, one might be moti-
vated to remove the major offending conditions, and then
repeat the PCA interpretation on the remaining condi-
tions (columns). The idea is that an independent source
of variation might be obscured by more dominant signals
or noise present in the data from the offending condition.
Our experience thus far leads us to think that this PCA
interpretation method will contribute to microarray
expression analysis, as one part of a panel of methods that
are sensitive to different features in a dataset, such as sam-
ple number, gene number, and distribution of variation
across the samples. The PCA method should be especially
useful for large, complex datasets that offer rich variation
among many samples. What is certain is that there are
almost always multiple sources of variation in a dataset
and that in any specific study their nature and relative
strength is informative, whether the origin is an easily-
understood biologic one, a technical one, or a poorly-
understood but nonetheless biologically pertinent one.
We are continuing to explore ways to improve our meth-
odology and software package. We anticipate further
advances will come with software infrastructure improve-
ments to permit covariate analyses of both column (sam-
ple) covariates and row (gene) covariates. The CompClust
dataset labeling capability [27] allows a user to attach
diverse and numerous labelings to rows or columns. For
example we can pull in additional row (gene probe)
annotations such as Gene Ontology (GO) functional
groups. Beyond explicitly comparing the NMI significance
of specific row partitionings for discrete covariates, we
GNF PC21 Extreme Gene Trajectory Plot with Tissues  Ordered by Significance Figure 4
GNF PC21 Extreme Gene Trajectory Plot with Tis-
sues Ordered by Significance. Trajectory plots for high 
and low extreme gene sets H21 (red, n = 37) and L21 (blue, n 
= 49) with tissues ordered by decreasing mean(H21) – 
mean(L21), and thus grouped by significance (UP21 group at 
left, FLAT21 group in middle and LOW21 group at right) at 
test1Thresh = 0.05. Table 5 lists the tissues within UP21 and 
DOWN21 that occur at each end of this plot.BMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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plan to add routines to CompClust to automatically indi-
cate when a group of genes are found to be enriched in
specific GO categories (as was done in our analyses
above), and more generally to handle large, discrete,
multi-valued distributions of values. Our use of NMI
treats discrete covariates as discrete random variables that
can have at most a single value per condition, and so does
not optimally address issue of multi-valued discrete ran-
dom variables (e.g. GNF data has covariate "concomitant
medications" with values like "aspirin", "tylenol", and
"aspirin & tylenol"). We are considering more elaborate
extensions of mutual information or alternatives that
might be able to take further advantage of such multi-val-
ued entries.
Availability and requirements
The PCA interpretation software is implemented as one
component of the CompClust Python package [9,27],
which is freely available for non-commercial use. The soft-
ware capability is also accessible through the CompClust-
Diabetes PC14 Sample Partitioning is Correlated with Certain Covariates Figure 5
Diabetes PC14 Sample Partitioning is Correlated with Certain Covariates. When sufficient covariate data is availa-
ble (a number of the measurements are missing for certain covariates), covariate distributions are compared across partitions 
and significant differences are reported (as in Table 7). When a covariate is identified as significantly correlated with a principal 
component's sample partitioning, covariate distribution plots can be generated to further investigate and evaluate the apparent 
relationship. For example, the diabetes dataset's PC14 extreme genes partition the samples into UP14 (n = 8), FLAT14 (n = 17) 
and DOWN14 (n = 10) based on their expression patterns. PC14's UP14 vs. {FLAT14+DOWN14} sample partitioning appears 
related to the Insulin_0 measure (sig = 0.001), and the {UP14+FLAT14} vs. DOWN14 partitioning appears related to Type2b_(%) 
(sig = 0.008). The mean expression of the PC14EG-high genes appears modestly correlated with Insulin_0 (r = 0.411) and with 
Type2b_(%) (r = 0.467). UP14 samples are in red, FLAT14 are black, and DOWN14 are blue.BMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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Table 6: GNF human expression principal components having extreme gene sets enriched in GO categories. Each of the GNF human 
expression PCEG sets, derived using an extremeThresh of 0.00001, was tested for Gene Ontology (GO) statistical enrichment. Terms 
that were enriched for a particular PC at 1% significance threshold are reported. 26 of the top 42 principal components produced 
extreme gene lists having significant GO term enrichment.
PCEG Set GO Description (p-value)
01 low GO:0006412 protein biosynthesis (4.51e-07)
03 high GO:0005201 extracellular matrix structural constituent (1.43e-08)
03 low GO:0007399 neurogenesis (5.05e-09)
GO:0007268 synaptic transmission (9.6e-09)
GO:0007417 central nervous system development (1.31e-08)
GO:0016820 hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances (4.85e-07)
04 low GO:0005201 extracellular matrix structural constituent (5.82e-07)
05 high GO:0007067 mitosis (3.43e-17)
GO:0051301 cell division (4.45e-17)
GO:0048015 phosphoinositide-mediated signaling (5.07e-13)
GO:0007049 cell cycle (1.79e-09)
GO:0006260 DNA replication (5.37e-08)
GO:0004674 protein serine/threonine kinase activity (1.09e-07)
GO:0005524 ATP binding (1.29e-07)
GO:0005634 nucleus (1.93e-07)
GO:0006468 protein amino acid phosphorylation (1.01e-06)
05 low GO:0045012 MHC class II receptor activity (8.59e-08)
GO:0006968 cellular defense response (5.07e-07)
GO:0006955 immune response (6.9e-07)
07 high GO:0005201 extracellular matrix structural constituent (3.27e-20)
GO:0005578 extracellular matrix (sensu Metazoa) (2.94e-15)
GO:0005581 collagen (1.76e-13)
GO:0006817 phosphate transport (2.79e-12)
GO:0007517 muscle development (8.27e-10)
GO:0005518 collagen binding (1.1e-07)
GO:0008201 heparin binding (8.6e-07)
GO:0007155 cell adhesion (1.55e-06)
GO:0005509 calcium ion binding (2.16e-06)
08 high GO:0007283 spermatogenesis (3.91e-10)
11 low GO:0042742 defense response to bacteria (1.09e-06)
13 high GO:0019884 antigen presentation, exogenous antigen (3.23e-16)
GO:0019886 antigen processing, exogenous antigen via MHC class II (5.1e-16)
GO:0045012 MHC class II receptor activity (5.1e-16)
GO:0006955 immune response (1.28e-15)
13 low GO:0006955 immune response (9.9e-16)
GO:0042110 T cell activation (1.15e-10)
GO:0007166 cell surface receptor linked signal transduction (1.64e-10)
GO:0004888 transmembrane receptor activity (1.25e-09)
GO:0006968 cellular defense response (2.05e-07)
GO:0019735 antimicrobial humoral response (sensu Vertebrata) (4.81e-07)
GO:0005515 protein binding (1.4e-06)
14 low GO:0005615 extracellular space (4.94e-24)
GO:0005319 lipid transporter activity (5.77e-11)
GO:0007596 blood coagulation (6.05e-11)
GO:0006953 acute-phase response (1.47e-10)
GO:0004867 serine-type endopeptidase inhibitor activity (6.14e-10)
GO:0004263 chymotrypsin activity (4.83e-09)
GO:0004295 trypsin activity (7.86e-09)
GO:0006810 transport (1.71e-08)
GO:0016042 lipid catabolism (6.48e-08)
GO:0005576 extracellular region (8.91e-08)
GO:0008201 heparin binding (1.05e-07)
GO:0006508 proteolysis and peptidolysis (4e-07)
GO:0006869 lipid transport (1.14e-06)
15 high GO:0005200 structural constituent of cytoskeleton (3.17e-12)
GO:0005882 intermediate filament (1.99e-10)
GO:0008544 epidermis development (4.44e-10)
GO:0007517 muscle development (9.24e-10)
15 low GO:0008201 heparin binding (1.71e-07)
GO:0005201 extracellular matrix structural constituent (3.95e-07)
16 low GO:0005179 hormone activity (4e-10)
GO:0005576 extracellular region (1.51e-07)
GO:0007565 pregnancy (1.57e-07)
17 high GO:0006955 immune response (6.06e-07)
18 high GO:0005882 intermediate filament (1.47e-11)
GO:0005200 structural constituent of cytoskeleton (5.67e-10)
GO:0005615 extracellular space (2.74e-08)
GO:0008544 epidermis development (1.75e-07)
GO:0005319 lipid transporter activity (9.61e-07)
GO:0005198 structural molecule activity (1.72e-06)
19 high GO:0005200 structural constituent of cytoskeleton (2.05e-07)
20 high GO:0005179 hormone activity (1.88e-08)BMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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Web web-based interface [29]. The software that
implements the web application is also included within
the CompClust software distribution.
Project name: the PCA interpretation component of Com-
pClust
Project home page: http://woldlab.caltech.edu/compclust
Operating system(s): platform independent (Windows,
Linux, Mac OS X)
Programming language: Python
Other requirements: Python 2.3 or higher (and some free
Python packages)
License: MLX Public License 1.0 (non-commercial use
allowed)
Use by non-academics: licence needed
We recommend that interested researchers use the web-
based application, CompClustWeb, from any platform to
review the PCA interpretation results for the GNF human
gene expression and Broad Institute human diabetes
expression data sets. We have written a CompClust PCA
interpretation tutorial that demonstrates how to use Com-
pClust's programming interface to generate PCA interpre-
tations. Following the tutorial requires that CompClust
and its Python prerequisites be installed. We created an
easy-to-use CompClustShell installer for Windows that
provides everything needed. For other operating systems
(e.g. Linux & OS X) we recommend that a software devel-
oper or system administrator help with the CompClust
source code installation. We are working to simplify
installation and plan to provide user-friendly installers for
other operating systems in the near future.
Methodology
We have developed the following algorithm for identify-
ing and analyzing multiple independent sources of vari-
ance present within multi-dimensional sample datasets,
in particular those that are produced by gene microarray
expression experiments. The overall approach can be sum-
marized as follows: 1) perform principal components
analysis of the dataset; for each principal component: 2)
identify the most extreme gene probes (those with the
highest or lowest weighting) for that principal compo-
nent; 3) identify and group any conditions in which those
extreme probes vary significantly; 4) identify any condi-
tion covariates that correlate well with the condition
grouping. By extending the interpretation of each princi-
pal component from extreme genes (rows) to ordered
groups of significant conditions (columns) and further to
identifying statistically significant correlations with col-
umn covariates, we attempt to make full use of the availa-
ble data, in an objective and data-driven way, to analyze
21 low GO:0007517 muscle development (7.01e-27)
GO:0008307 structural constituent of muscle (4.15e-23)
GO:0003779 actin binding (6.2e-14)
GO:0006941 striated muscle contraction (5.69e-10)
GO:0005859 muscle myosin (1.99e-08)
22 high GO:0016042 lipid catabolism (9.41e-08)
GO:0004263 chymotrypsin activity (1.94e-06)
23 high GO:0019825 oxygen binding (1.9e-08)
GO:0005344 oxygen transporter activity (2.67e-07)
GO:0015671 oxygen transport (3.8e-07)
24 low GO:0007517 muscle development (8.02e-15)
GO:0008307 structural constituent of muscle (2.11e-12)
GO:0003779 actin binding (3.61e-09)
GO:0005319 lipid transporter actiGO:0005856 cytoskeleton (1e-06)
26 high GO:0005576 extracellular region (3.7e-10)
GO:0005319 lipid transporter activity (2.31e-08)
GO:0006869 lipid transport (9.09e-08)
26 low GO:0008307 structural constituent of muscle (1.19e-08)
GO:0005344 oxygen transporter activity (2.67e-07)
GO:0015671 oxygen transport (3.8e-07)
29 high GO:0005615 extracellular space (1.8e-06)
32 low GO:0005576 extracellular region (3.34e-15)
GO:0005615 extracellular space (6.56e-07)
GO:0005179 hormone activity (2.15e-06)
35 low GO:0007585 respiratory gaseous exchange (4e-09)
39 high GO:0005576 extracellular region (2.35e-07)
40 high GO:0005179 hormone activity (8.22e-08)
GO:0005576 extracellular region (9.39e-07)
42 high GO:0005179 hormone activity (8.22e-08)
GO:0005576 extracellular region (9.39e-07)
Table 6: GNF human expression principal components having extreme gene sets enriched in GO categories. Each of the GNF human 
expression PCEG sets, derived using an extremeThresh of 0.00001, was tested for Gene Ontology (GO) statistical enrichment. Terms 
that were enriched for a particular PC at 1% significance threshold are reported. 26 of the top 42 principal components produced 
extreme gene lists having significant GO term enrichment. (Continued)BMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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and provide meaningful interpretations of the diverse
sources of variation present within the dataset.
Determine the principal components of the dataset
Our dataset D consists of nc columns (e.g. tissue samples
or conditions) and nr row vectors (e.g. gene probes), each
row vector xi ∈ ℜnc where i ∈ [1, nr]. Such a dataset is usu-
ally represented as a two-dimensional nr  ×  nc  matrix
(where nr > nc). The dataset may optionally have nk sup-
plemental covariate annotations C associated with each
row or column. Each annotation Ck where k ∈ [1, nk] can
be either discrete (e.g. sex) or continuous (e.g. age), to per-
mit the association of one discrete value per column (e.g.
values male or female), or one continuous value per col-
umn (e.g. values 12, 16, or 42).
Our procedure starts by employing principal components
analysis (PCA) to sequentially identify a series of new
basis vectors or axes PC1, PC2, ...PCnc in the high-dimen-
sional column space ℜn that are each aligned sequentially
to capture the most as-yet unexplained variance. This is
accomplished by applying the numeric procedure singu-
lar value decomposition (SVD) to the covariance matrix of
D, cov(D), to produce the decomposition cov(D) = USVT
that contains the eigenvectors of cov(D) in the columns of
U and eigenvalues in the diagonal of S such that the eigen-
values are sorted by descending size. Each covariance
eigenvector, or principal component PC1,  PC2, ...PCnc,
explains a fraction of the total variance contained in the
dataset, and each principal component PCn+1 is orthogo-
nal to the previous principal component PCn. such that
they define the basis of a new vector space P. These results
are made available to the users in the form of nc plots, one
for each of the principal component vectors, as well as a
plot of the singular values contained in the diagonal of S
to indicate the relative amount of variance each compo-
nent explains.
Identify extreme gene probes for each principal 
component
Next, we project each data point xi (corresponding to a
gene probe, or row vector) into the new coordinate system
by P = DU, effectively rotating the entire data point set D
into the new principal component axes space, producing
the rotated data set P. Each data point pi in the rows of P
corresponding to xi has a coordinate for each principal
component axis that describes where the data point pi lies
when projected along each axis PC1, PC1, ...PCnc. For each
principal component PCn (n ∈ [1, nc]) we select a set of
data points from each end of that principal component
axis- these are the extreme points for PCn, called the prin-
cipal component extreme genes, or PCEGs for conven-
ience. The PCEGs can be identified and ranked in one of
two ways: by identifying points having a low probability
(p < = extremeThresh) of belonging to a Gaussian fit to the
distribution of points along the PCn axis, or by taking a
fixed number of nExtreme points at each tail of the distri-
bution. Hn is the resulting set of data points having the
highest coordinate values for PCn, and Ln is the resulting
set of data points having the lowest coordinate values for
PCn. These high and low extreme gene point sets are
informative in and of themselves because they represent
the most extreme of the data points along a principal axis
of variation. As such, the high and low PCEG sets are some
of the primary outputs generated by our procedure. We
use the term "extreme" in a very general sense, in that the
points stand out because they are far from the main distri-
bution. We do not mean to imply that such points are
Table 7: Diabetes dataset covariates identified as correlated with principal components. Results of a search for covariates with value 
distributions having significant differences in either UPn vs. DOWNn, {UPn+FLATn} vs. DOWNn, or UPn vs. {FLATn+DOWNn} are shown 
below. An "X" indicates the covariate's values varied significantly in the corresponding principal component's sample partitioning. 11 
(out of 53) covariates were identified at a 1% significance level (minSetSize = 5) in 10 of the first 20 principal components. To investigate 
further, corresponding plots of covariate value distributions within sample partitions can be generated, such as the covariate plots for 
PC14 (see Figure 5).
Principal Component Number
1234567891 01 11 21 31 41 51 61 71 81 92 0
Cap_(mm2) X
Cap__Type2b_(mean_n) X
Centroid_(Using_34_OXPHOS-CR_Genes) X
Insulin_0 X
Patient_# X
Type1_Min_Area_(um2) X
Type2a_(n) X
Type2a_Min_Area_(um2) X
Type2b_(%) X
Type2b_(n) X
UQCRB_(209065_at) XBMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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either biologically relevant or nuisance data that should
be removed; rather we are interested in these points in an
unbiased way. By further analyzing their pattern of expres-
sion in the original axes we hope to gain a better under-
standing of their possible biologic significance.
Identify significant conditions for each principal 
component
The extreme gene points comprising Hn are located near
one edge of the high-dimensional cloud of points, and
points Ln are near the opposite edge. Thus, points Hn are
likely to have coordinate values that are maximally differ-
ent from points Ln in a subset of the original column space
coordinate system. Our procedure next seeks to identify in
which of the original columns (the original axes or
dimensions) we find the greatest difference of values for
points Hn versus points Ln. We do this by comparing dis-
tributions of values in Hnj versus Lnj for each of the original
columns j (j ∈ [1, nc]). A two-sided Wilcoxon rank sum
test is used to estimate the likelihood that these two sets
of values are drawn from the same distribution [39]; the
resulting p-values for each column are used to rank order
and group the columns, rather than as actual probabili-
ties. Columns having a likelihood less than a user-defined
significance level test1Thresh are identified and placed into
one of two column sets: UPn for those where column j has
mean(Hnj) > mean(Lnj), and DOWNn for those columns j
where mean(Hnj) <mean(Lnj). Remaining columns that do
not show significant variation are placed in the column
set FLATn. The column sets are also meaningful outputs of
our procedure, as UPn and DOWNn describe the groups of
columns in which the extreme genes Hn and Ln vary signif-
icantly. Our procedure can output these columns and col-
umn sets in various orders simply as an aid to human
interpretation, including: original column order; grouped
by set and within set ordered by the Wilcoxon p-value sig-
nificance; ordered by mean difference, mean(Hnj) –
mean(Lnj); or ordered by the eigenvector column loading.
Taken together, the PCEG point sets and significant col-
umn sets should provide valuable insight to researchers
wishing to interpret each of the sources of variation iden-
tified by the principal components procedure.
Interpret each principal component using covariate 
annotations
When provided additional covariate annotations C, the
procedure seeks to determine which, if any of the annota-
tions Ck are well correlated with the partitioning of col-
umns into the sets {UPn,  FLATn,  DOWNn}. A discrete
annotation Ck containing m unique values V1, V2, ... Vm
also defines a partitioning of the columns {KV1, KV2, ...,
KVm} where KV1 is the set of columns that share the value
V1, KV2 are those that share value V2, and so on. An infor-
mation theoretic measure known as normalized mutual
information (NMI) [28] describes the degree to which two
discrete random variables share information. When there
is high mutual information, knowing the value of one of
the variables should be useful predictor of the other vari-
able. (See [9] for a description of the merits of NMI in
terms of clustering and understanding the relationships
between clusterings.) We construct the 3 x m confusion
matrix to compare the {UPn, FLATn, DOWNn} column
partitioning with the {KV1, KV2, ..., KVm} partitioning and
calculate an NMI score between the partitionings. Because
the usual NMI score is not symmetric (i.e. NMI(r,c)  ≠
NMI(c,r)), we use a variant that we refer to as the average
NMI score, which is simply the average of the NMI of the
confusion matrix and the NMI of the transpose of the con-
fusion matrix. Those covariates Ck having an average NMI
greater than a user defined threshold nmiThresh are added
to the set of significant covariate annotations An.
We apply a different approach when evaluating the Ck that
are continuous covariates. We need to assess whether each
principal component's {UPn,  FLATn,  DOWNn} column
partitioning correlates with each Ck distribution of values.
We can separately score three different partitioning
schemes, UPn vs. DOWNn, {UPn+FLATn} vs. DOWNn, and
UPn vs.{FLATn+DOWNn}, by determining if Ck's value dis-
tributions differ significantly across the partition. E.g.
does Ck within UPn have a different distribution than Ck
within DOWNn? Next, does Ck within {UPn + FLATn} have
a different distribution than Ck within DOWNn? Finally,
does Ck within UPn have a different distribution than Ck
within {FLATn+DOWNn}? For each partition scheme we
again use a two-tailed Wilcoxon rank sum test, including
the small sample adjustments when sample size is less
than 10, to determine whether the covariate's value distri-
butions on each side of the partitioning differ significantly
from each other. A minSetSize parameter can be specified
as desired to reduce false positives when set sizes are very
small, e.g. when comparing a distribution of 2 values vs.
7 values. Thus we calculate the Wilcoxon p-value for three
partitionings of columns: UPn vs. DOWNn, {UPn+FLATn}
vs. DOWNn, and UPn vs. {FLATn+DOWNn}. Those covari-
ates having a p-value less than the user defined threshold
test2Thresh for any of the three partitionings are added to
the set of significant covariate annotations An.
Upon completion of the covariate analysis, covariates in
the set An, that previously met user-controlled significance
thresholds are reported by the software. Covariate reports
provide the following information: For discrete-valued
covariates, corresponding confusion matrices and average
NMI scores are reported; for continuous-valued covari-
ates, the three Wilcoxon  p-values are reported together
with supporting plots illustrating the covariate distribu-
tions. There is no guarantee that any covariates will be sig-
nificantly related to a principal component. Conversely,
spurious relationships might be reported, especially in theBMC Bioinformatics 2006, 7:194 http://www.biomedcentral.com/1471-2105/7/194
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case of small numbers of samples due to small column
partitions. The tool simply points to those covariates
related to a principal component that also satisfy a user-
controlled significance threshold. It is up to the investiga-
tor to consider these hypotheses and to confirm the inter-
esting ones through further investigation.
Terminating condition
We have shown that some large-scale expression datasets
have biologically pertinent structure that is revealed by
deep PC analysis that goes well beyond the first few prin-
cipal components. However there are limits to the depth
of mining and these limits depend on both size and char-
acter of the dataset. In all cases, the last principal compo-
nent is not free to seek a source of variation because it
must be orthogonal to all prior nc-1  components. To
some degree that is also true of some portion of latter
principal components that explain ever-diminishing frac-
tions of the variance. We suggest that a natural terminat-
ing condition exists: When a principal component cannot
find any columns in which the extreme gene sets show sig-
nificant differences, there is no need to proceed to subse-
quent principal components. We observe that this
condition is often not met because the extreme genes are
typically differentially expressed in at least a few of the
original columns (the original axes or dimensions), even
for the most minor principal components. We also
observe that variants of a dataset (e.g. representative col-
umn subsets) can affect the relative ordering, but not the
existence, of multiple factors or sources of variation that
are reflected in the minor principal component regime.
We may therefore choose to investigate all principal com-
ponents, but do so with the expectation that minor prin-
cipal components will describe increasingly subtle sources
of variation, which can, and often do, include noisy proc-
esses inherent in the data source.
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